Illumina, Inc. (ILMN)

NASDAQ: ILMN · IEX Real-Time Price · USD
+0.38 (0.20%)
At close: Jun 24, 2022 4:00 PM
+0.59 (0.30%)
After-hours: Jun 24, 2022 7:57 PM EDT
Market Cap 30.47B
Revenue (ttm) 4.66B
Net Income (ttm) 700.00M
Shares Out 157.10M
EPS (ttm) 4.56
PE Ratio 42.58
Forward PE 44.84
Dividend n/a
Ex-Dividend Date n/a
Volume 4,233,231
Open 195.71
Previous Close 193.55
Day's Range 190.85 - 195.98
52-Week Range 180.00 - 526.00
Beta 1.00
Analysts Buy
Price Target 347.95 (+79.4%)
Earnings Date Aug 4, 2022

About ILMN

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as canc... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Jul 28, 2000
CEO Jay Flatley
Employees 9,800
Stock Exchange NASDAQ
Ticker Symbol ILMN
Full Company Profile

Financial Performance

In 2021, Illumina's revenue was $4.53 billion, an increase of 39.73% compared to the previous year's $3.24 billion. Earnings were $762.00 million, an increase of 16.16%.

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price forecast is 347.95, which is an increase of 79.42% from the latest price.

Price Target
(79.42% upside)
Analyst Consensus: Buy
Stock Forecasts


10 Stocks to Buy When They're Down

When you buy shares of stock, you become a partner in a business. Perhaps I'm stating the obvious, but I doubt all investors see their purchases that way.

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

New assay brings  validated HRD technology from Myriad Genetics to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development a...

Other symbols: MYGN

GRAIL and Fountain Health Insurance Partner to Provide Coverage of Galleri® Multi-cancer Early Detection Test

MENLO PARK, Calif., & NAPLES, Fla.--(BUSINESS WIRE)--GRAIL and Fountain Health announced a partnership that will offer Galleri® to Fountain Health customers at 100% coverage.

Why Illumina Stock Is Sinking Today

The genomic-sequencing company's CFO is unexpectedly leaving for another company.


SAN DIEGO , June 9, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami, Chief Strategy and Corporate Deve...

Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions

SAN DIEGO , June 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and presentations ...

GRAIL and England's National Health Service (NHS) Present Trial Design for Largest Study of Multi-Cancer Early Detect...

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL announced that the study design of the NHS-Galleri trial was presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

GRAIL and Ochsner Health Launch New Initiatives to Improve Cancer Detection Rates in Louisiana

MENLO PARK, Calif. & NEW ORLEANS--(BUSINESS WIRE)--GRAIL and Ochsner Health announced a multi-faceted partnership to improve cancer detection rates in Louisiana using Galleri®.

Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine f...

SAN DIEGO , June 2, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abst...

GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatmen...

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL announced a broad strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic assays.

Other symbols: AZN

Illumina's (ILMN) GRAIL to Assess Galleri Test With New Deal

Illumina (ILMN) GRAIL's recent collaboration is part of REFLECTION, a real-world observational study assessing the performance of the Galleri MCED test in clinical settings.

Here's Why Investors Should Retain Illumina (ILMN) Stock Now

Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.

GRAIL Announces Collaboration With U.S. Department of Veterans Affairs and the Veterans Health Foundation to Evaluate...

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL collaborates with the U.S. Department of Veterans Affairs Veterans Health Administration and the Veterans Health Foundation to provide Galleri.

Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI

Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.

EU court to rule July 13 on Illumina challenge of EU review of Grail -sources

A European court will decide on July 13 whether U.S. life sciences company Illumina's $8 billion cash-and-stock takeover of Grail should be scrutinised by EU antitrust regulators, people familiar with t...

Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger

Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.

Illumina Ventures Announces Promotion and Additions to its Investment Team

FOSTER CITY, Calif.--(BUSINESS WIRE)--Illumina Ventures promotes Malek Faham to Chief Scientist, and adds Charles Lin as Principal and Dave Johnson as Entrepreneur in Residence.

Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted The...

First companion diagnostic claim for Illumina's TruSight™ Oncology Comprehensive (EU) test enables targeted therapy with Bayer's VITRAKVI® (larotrectinib) for patients with NTRK fusion cancer SAN DIEGO ...

This Gene Sequencing Company Is A Better Pick Over Walgreens Stock

We think that Illumina stock (NASDAQ: ILMN) currently is a better pick compared to the Walgreens stock (NYSE: WBA), despite it being the more expensive of the two, trading at 7.8x trailing revenues comp...

Illumina's (ILMN) GRAIL, Intermountain Healthcare Expand Tie-Up

Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.

Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care

Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient's cancer, which may influence choice of treatment based on cancer stage and type S...

GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to El...

MENLO PARK, Calif. & SALT LAKE CITY--(BUSINESS WIRE)-- #DetectCancerEarly--Intermountain Healthcare will offer Galleri®, GRAIL's multi-cancer early detection blood test, as a complement to existing sing...

Karen Firestone's top stock picks: Vertex Pharma, Moderna

Kari Firestone, Aureus Asset Management, joins 'Closing Bell: Overtime' to discuss the biotech bounce and her top stock picks.

Other symbols: MRNAVRTXIQV

Comprehensive Study Establishes Cost of Late Detection and Treatment of Cancer

An analysis of 2 million Medicare beneficiaries establishes the cost of cancer by stage and time since diagnosis for 17 common cancers. The later the stage at diagnosis, the higher the cost, and this co...

Why Illumina Shares Are Plunging Today?

A jury in the U.S. District Court for the District of Delaware rendered a verdict that Illumina Inc (NASDAQ: ILMN) willfully infringed the U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Gen...